Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Alyssa L. Kennedy, MDPhD, Kasiani C. Myers, MD, James Bowman, PhD, Christopher J. Gibson, MD, Gwen M. Muscato, Robert Klein, Kaitlyn Ballotti, Nicholas Camarda, Elissa M. Furutani, MD, Chad E. Harris, MS, Shanshan Liu, PhD, Ashley Galvin, Maggie Malsch, MSN, RN, David C. Dale, MD, John M Gansner, MD PhD, Taizo A. Nakano, MD, Alison A. Bertuch, MD, Adrianna Vlachos, MD, Jeff H. Lipton, MD PhD, Paul Castillo, MD, James Connelly, John Edwards, MD, Nobuko Hijiya, MD, Richard Ho, MD, Inga Hofmann, MD, James N Huang, MD, Sioban B. Keel, MD, Adam J. Lamble, MD, Bonnie W Lau, MD PhD, Kelly J. Walkovich, MD, Maxim Norkin, MD, Wendy Stock, MD, Steffen Boettcher, Christian Brendel, PhD, Elliot Stieglitz, MD, Mark D. Fleming, MD DPhil, Stella M. Davies, PhD MBBS, MRCP, Edie A. Weller, Chris Bahl, PhD, Scott L. Carter, PhD, Akiko Shimamura, MD PhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137125

Published: 2020

Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2018-99-110543

Published: 2018

Journal Articles

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Maria Rhida Bautista, MD FRACP, FRCPA, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2018-99-119472

Published: 2018

Journal Articles

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Anti-Thymocyte Globulin As Graft Versus Host Disease Prophylaxis

Queralt Salas Gay, MD, Arjun Law, MDDM, Wilson Lam, MD, Zeyad Al-Shaibani, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MDDM, Dennis Dong Hwan Kim, MD PhD, Jeff H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MDDM

Blood (2018) 132 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2018-99-119417

Published: 2018

Journal Articles

High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation

Queralt Salas Gay, MD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MDDM, Dennis Dong Hwan Kim, MD PhD, Jeff H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MDDM, Arjun Law, MDDM

Blood (2018) 132 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2018-99-119162

Published: 2018

Journal Articles

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Mohammed A. Marei, Eshetu G Atenafu, MSc, P.Stat, Arjun Law, MD DM, Wilson Lam, MD, Rajat Kumar, MD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD

Blood (2018) 132 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2018-99-113884

Published: 2018

Journal Articles

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Michael W. Deininger, MD PhD, Vamsi Kota, MBBS, Jeff H. Lipton, MD PhD, Dragana Milojkovic, MBBS, PhD, Valentín García Gutiérrez, PhD, Eric Leip, PhD, Sonja Nick, MSc, Andreas Hochhaus, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Tim H. Brummendorf, MD

Blood (2018) 132 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2018-99-110798

Published: 2018

Journal Articles

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Eric Anthony Coomes, MD, Amanda Jacques, BScPharm, RPh, ACPR, Fotios V. Michelis, MD PhD, Dennis (Dong-Hwong) Kim, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Uday Deotare, MD

Blood (2017) 130 (Supplement 1): 5479.

https://doi.org/10.1182/blood.V130.Suppl_1.5479.5479

Published: 2017

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Dennis Dong Hwan Kim, MD PhD, Mary Lynn Savoie, MD, Isabelle Bence-Bruckler, MD FRCPC, Lothar B. Huebsch, MD, Marc Lalancette, MDFRCP-C, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Donna L. Forrest, MD, Jeff H. Lipton, MD PhD

Blood (2016) 128 (22): 1907.

https://doi.org/10.1182/blood.V128.22.1907.1907

Published: 2016

Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Jeff H. Lipton, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD

Blood (2013) 122 (21): 4025.

https://doi.org/10.1182/blood.V122.21.4025.4025

Published: 2013

Journal Articles

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Jorge E. Cortes, MD, H. Jean Khoury, Jeff H Lipton, MD, Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Eric Leip, Virginia Kelly, Nadine Besson, Kathleen Turnbull, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2793.

https://doi.org/10.1182/blood.V120.21.2793.2793

Published: 2012

Journal Articles

Global Trends in Hematopoietic Cell Transplantation.

Helen Baldomero, Mahmoud Aljurf, MD, Luis Fernando Bouzas, MD, MSC, Alois Gratwohl, MD, Yoshihisa Kodera, MD, PhD, Jeff H Lipton, MD, J. Alejandro Madrigal, MD, PhD, Lida Minako, Nicolas Novitzky, MD, PhD, Marcelo C Pasquini, MD, MS, Jakob R. Passweg, Adriana Seber, MD, Jeffrey Szer, MBBS, Dietger Niederwieser, MD

Blood (2012) 120 (21): 3143.

https://doi.org/10.1182/blood.V120.21.3143.3143

Published: 2012

Journal Articles

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Naheed Alam, MBBS, Anna Lambie, NP, Yvette Neme Yunes, MD, Feras Alfraih, MD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeff H Lipton, MD, Hans A. Messner, M.D./Ph.D

Blood (2012) 120 (21): 4501.

https://doi.org/10.1182/blood.V120.21.4501.4501

Published: 2012

Journal Articles

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Tim H Brümmendorf, Hagop M. Kantarjian, MD, Carlo Gambacorti-Passerini, Francois Guilhot, Luke Akard, MD, Vaishali Doshi, Jeff H Lipton, MD, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 69.

https://doi.org/10.1182/blood.V120.21.69.69

Published: 2012

NARROW

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Anti-Thymocyte Globulin As Graft Versus Host Disease Prophylaxis

High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Global Trends in Hematopoietic Cell Transplantation.

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only